var data={"title":"General anesthesia: Intravenous induction agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">General anesthesia: Intravenous induction agents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/contributors\" class=\"contributor contributor_credentials\">Liza M Weavind, MBBCh, FCCM, MMHC</a></dd><dd><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/contributors\" class=\"contributor contributor_credentials\">Adam King, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/contributors\" class=\"contributor contributor_credentials\">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/contributors\" class=\"contributor contributor_credentials\">Nancy A Nussmeier, MD, FAHA</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 20, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1503167298\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, and <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> are the intravenous (IV) sedative-hypnotic agents commonly used to induce general anesthesia (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). After IV injection, these induction agents have rapid onset due to their high lipid solubility allowing penetration of the blood&ndash;brain barrier, and the high proportion of the cardiac output (CO) that perfuses the brain (the effect site). These agents also have a short duration of action due to rapid redistribution from the brain to other tissues, primarily muscle and fat. Typically, one or more adjuvant medications is administered to supplement induction of general anesthesia.</p><p>This topic will discuss the advantages, adverse effects, dosing, and pharmacokinetics of the IV sedative-hypnotics (<a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">methohexital</a>) and adjuvants (opioids, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>) during induction of general anesthesia. Selection of an induction technique is discussed separately (see <a href=\"topic.htm?path=general-anesthesia-induction\" class=\"medical medical_review\">&quot;General anesthesia: Induction&quot;</a>). Other uses of sedative-hypnotics, opioids, and adjuvant agents are discussed in other topics:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=procedural-sedation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">&quot;Procedural sedation in adults outside the operating room&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4070595924\"><span class=\"h1\">DOSING CONSIDERATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial doses of intravenous (IV) sedative-hypnotic and adjuvant agents are individualized. Additional doses, if needed, are titrated to induce stage III surgical anesthesia with unconsciousness, amnesia, immobility, and absence of response to noxious stimulation (<a href=\"image.htm?imageKey=ANEST%2F107796\" class=\"graphic graphic_table graphicRef107796 \">table 2</a>).</p><p>Factors affecting dosing include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individual patient variations in pharmacodynamics (ie, what the drug does to the patient) and pharmacokinetics (ie, what the patient does to the drug). For example, induction doses are reduced in patients with impaired renal or hepatic function, hemodynamic abnormalities due to hypovolemia, vasodilation, or myocardial dysfunction, and in older adults. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H251746966\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Selection and dosing of anesthetic agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk of dose-related adverse effects such as hypotension or respiratory depression.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coadministration of adjuvant drugs. When anesthetic drugs from different classes are combined, the hypnotic effects are often synergistic rather than merely additive. Synergy is particularly common when drugs acting primarily on gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptors (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>) are combined with drugs acting on other receptor types [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below.)</p><p/><p>Because of this complexity, it is not possible to recommend fixed dosing regimens for induction agents. It is best to titrate drug doses in increments during induction, and the time between titrated doses may be brief (20 to 60 seconds). Although there are no clinical trials to support specific dosing or titration schemes in specific situations, the following general principles are useful:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Titration of anesthetic agents during induction of anesthesia requires continuous assessment of the patient's heart rate (HR), blood pressure (BP), and state of consciousness (eg, responses to voice, tactile stimulation such as the lash reflex, or placement of an oral airway).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While processed electroencephalogram (EEG) monitoring may be used to assess anesthetic depth (eg, bispectral index [BIS] or entropy signal changes), at least 30 seconds are required for EEG signal processing. This lag between the patient's current state of consciousness and the processed EEG value limits the utility of such technology during induction of anesthesia [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Doses cannot be titrated to effect if rapid sequence induction of anesthesia is required. The anesthesia provider must select reasonable doses based on the patient's condition and planned coadministration of one or more adjuvant agents. Administration of selected induction agents is rapidly followed by laryngoscopy and intubation of the trachea. Immediately after successful intubation, it may be necessary to administer additional doses of anesthetic agents <span class=\"nowrap\">and/or</span> drugs to treat adverse hemodynamic effects.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opioids are particularly useful adjuvants because they allow reduction in the dose of sedative-hypnotic agent and also attenuate the hemodynamic response to laryngoscopy and endotracheal intubation. (See <a href=\"#H240924670\" class=\"local\">'Opioids'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H2269410\"><span class=\"h1\">PROPOFOL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is the intravenous (IV) induction drug of choice for most patients because of its rapid onset and recovery, beneficial antiemetic and other properties, and relatively benign adverse side effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>).</p><p>The primary mechanism of action for <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> is activation of the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor complex, the chief inhibitory neurotransmitter of the central nervous system. Propofol is also an antagonist of the N-methyl-D-aspartate (NMDA) receptor.</p><p>The formulation for <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> (2,6-diisopropylphenol) is an aqueous emulsion containing egg phosphatide (intralipid), soybean oil, and glycerol.</p><p class=\"headingAnchor\" id=\"H2657717339\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> has the following advantages (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid onset (30 to 45 seconds) and recovery.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiemetic properties. <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is a good choice for patients at increased risk for postoperative nausea and vomiting (PONV) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=postoperative-nausea-and-vomiting\" class=\"medical medical_review\">&quot;Postoperative nausea and vomiting&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antipruritic properties. <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is a good choice for patients who will receive opioids, which often cause pruritus.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchodilatory properties with decreased airway resistance [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/4,5\" class=\"abstract_t\">4,5</a>]. <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is useful for induction in patients with bronchospasm and asthma [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=anesthesia-for-adult-patients-with-asthma#H1234674358\" class=\"medical medical_review\">&quot;Anesthesia for adult patients with asthma&quot;, section on 'Anesthetic agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticonvulsant properties. <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> decreases cerebral metabolic rate of oxygen consumption (CMRO<sub>2</sub>), with consequent reduction in cerebral blood flow (CBF) and intracranial pressure (ICP). It may be advantageous in patients with brain injury, but mean arterial (MAP) pressure must be maintained [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/7,8\" class=\"abstract_t\">7,8</a>]. (See <a href=\"topic.htm?path=anesthesia-for-patients-with-acute-traumatic-brain-injury#H128065263\" class=\"medical medical_review\">&quot;Anesthesia for patients with acute traumatic brain injury&quot;, section on 'Choice of anesthetic agents'</a> and <a href=\"topic.htm?path=anesthesia-for-intracranial-neurovascular-procedures-in-adults\" class=\"medical medical_review\">&quot;Anesthesia for intracranial neurovascular procedures in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suitability for patients with renal <span class=\"nowrap\">and/or</span> hepatic insufficiency [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/9-15\" class=\"abstract_t\">9-15</a>]. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis#H3801553334\" class=\"medical medical_review\">&quot;Anesthesia for the patient on dialysis&quot;, section on 'Induction'</a> and <a href=\"topic.htm?path=anesthesia-for-the-patient-with-liver-disease#H2437853593\" class=\"medical medical_review\">&quot;Anesthesia for the patient with liver disease&quot;, section on 'Sedative hypnotics'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2269447\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> has the following potential adverse effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent hypotension after bolus injection. This is due primarily to venous and arterial dilation, as well as decreased contractility [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/16-21\" class=\"abstract_t\">16-21</a>]. Heart rate (HR) is minimally affected because the baroreceptor reflex is blunted.</p><p/><p class=\"bulletIndent1\">When used for induction, systolic blood pressure (BP) decreases to &lt;90 mmHg in 16 percent of patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/18\" class=\"abstract_t\">18</a>]. Severe hypotension may occur in patients who are hypovolemic or hemodynamically compromised, as well as in older patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"#H4201415421\" class=\"local\">'Dosing'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent respiratory depression (decreases in respiratory rate, tidal volume, and ventilatory responses to hypoxia and hypercarbia). Apnea lasting a few minutes after an induction dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> occurs in approximately one-third of healthy patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pain on injection. This occurs in approximately two-thirds of patients due to venous irritation caused by <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> itself rather than its lipid emulsion [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/22\" class=\"abstract_t\">22</a>]. Typically, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> <span class=\"nowrap\">and/or</span> an opioid is coadministered with propofol to minimize this pain [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/22-27\" class=\"abstract_t\">22-27</a>]. However, in patients who may develop hemodynamic instability, these adjuvant agents may be eliminated or reduced. Injection of propofol into a larger or central vein also minimizes pain. (See <a href=\"#H1973711502\" class=\"local\">'Lidocaine'</a> below and <a href=\"#H240924670\" class=\"local\">'Opioids'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contamination risk. Despite the addition of antimicrobials, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> preparations support rapid bacterial growth due to the lipid emulsion containing egg lecithin, glycerol, and soybean oil. Fever, infection, sepsis, and death have been reported [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/28\" class=\"abstract_t\">28</a>]. Risk is minimized by:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Using an aseptic technique in drug preparation</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Avoiding multidose use from a single vial for more than one patient </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Discarding opened <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> after six hours</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare allergic reactions [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management#H9\" class=\"medical medical_review\">&quot;Perioperative anaphylaxis: Clinical manifestations, etiology, and management&quot;, section on 'Hypnotic induction agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1745064393\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types, including opioids, benzodiazepines, and volatile anesthetics, may produce synergistic anesthetic effects. Thus, reduction of the <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> dose is prudent [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1,30\" class=\"abstract_t\">1,30</a>]. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below and <a href=\"#H1872411706\" class=\"local\">'Dosing'</a> below.)</p><p class=\"headingAnchor\" id=\"H165838481\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is highly lipid-soluble, resulting in very rapid onset. The half-life of equilibration <span class=\"nowrap\">(t1/2</span> keo) between plasma and effect site (the brain) is 1.5 to 2.6 minutes [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/31\" class=\"abstract_t\">31</a>].</p><p><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> has a short duration of action (two to eight minutes) because it is rapidly redistributed from the brain to other tissues into a very large volume of distribution (3 to 12 <span class=\"nowrap\">L/kg)</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/32\" class=\"abstract_t\">32</a>]. Clearance of propofol is also rapid (20 to 30 <span class=\"nowrap\">mL/kg/minute),</span> in excess of liver blood flow, which suggests extrahepatic metabolism [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/9\" class=\"abstract_t\">9</a>]. However, most of the drug is conjugated in the liver, and the metabolites are pharmacologically inactive. Although propofol has a long terminal elimination half-life of 4 to 30 hours, actual plasma concentrations remain low throughout this phase after a typical induction dose [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p class=\"headingAnchor\" id=\"H1872411706\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The induction dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> for general anesthesia is 1 to 2.5 <span class=\"nowrap\">mg/kg</span> (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/35\" class=\"abstract_t\">35</a>]. </p><p>Dose-dependent hypotension is avoided by reducing the initial dose and titrating <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> in increments, particularly in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Older age (suggested dose is 1 to 1.5 <span class=\"nowrap\">mg/kg)</span>. Dose reduction is prudent due to changes in pharmacodynamics, as well as changes in clearance and central volume of distribution [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183400993\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Sedative-hypnotics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypovolemia or myocardial dysfunction (suggested dose is &le;1 <span class=\"nowrap\">mg/kg)</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/16,36\" class=\"abstract_t\">16,36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types because of synergistic effects [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1,30\" class=\"abstract_t\">1,30</a>].</p><p/><p class=\"headingAnchor\" id=\"H307136729\"><span class=\"h1\">ETOMIDATE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> is often selected to induce general anesthesia in patients with hemodynamic instability due to any cause because it has rapid onset without changes in blood pressure (BP), cardiac output (CO), or heart rate (HR). It is the most hemodynamically neutral of the sedative-hypnotic agents used for induction of general anesthesia (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/37\" class=\"abstract_t\">37</a>].</p><p><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> is an imidazole derivative that acts directly on the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>)<sub> </sub>receptor complex, blocking neuroexcitation and producing anesthesia.</p><p class=\"headingAnchor\" id=\"H3248597381\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> has the following advantages (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superior hemodynamic stability compared with other induction agents. <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> does not cause vasodilation or myocardial depression, and does not increase sympathetic tone. Thus, BP and HR remain stable. Compared with other anesthetic induction agents, etomidate has the most favorable therapeutic index (ratio of median lethal dose [LD<sub>50</sub>] to median effective dose [EC<sub>50</sub>]) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid onset and recovery, similar to <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticonvulsant properties. <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> decreases cerebral metabolic rate of oxygen consumption (CMRO<sub>2</sub>), with consequent reduction in cerebral blood flow (CBF) and intracranial pressure (ICP). Thus, it may be advantageous in hemodynamically unstable patients with head injury or stroke. (See <a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room#H15\" class=\"medical medical_review\">&quot;Induction agents for rapid sequence intubation in adults outside the operating room&quot;, section on 'Head injury or stroke'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H262499028\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> has the following potential adverse effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A high incidence (approximately 30 percent) of postoperative nausea and vomiting (PONV) compared with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pain on injection occurs in up to 80 percent of patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/39\" class=\"abstract_t\">39</a>]. This is caused by venous irritation due to the low pH (6.9) of the 35 percent propylene glycol used in <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> formulations [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/7\" class=\"abstract_t\">7</a>]. Pain is minimized or eliminated when etomidate is injected into a larger or central vein. Although coadministration of <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> or an opioid may minimize this pain, etomidate is often selected to induce anesthesia in patients with hemodynamic instability in whom these adjuvant agents are usually avoided or the dose is reduced. (See <a href=\"#H1973711502\" class=\"local\">'Lidocaine'</a> below and <a href=\"#H240924670\" class=\"local\">'Opioids'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-related involuntary myoclonic movements occur in 50 to 80 percent of patients during induction [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/39,41-44\" class=\"abstract_t\">39,41-44</a>]. This is due to subcortical disinhibition and is unrelated to cortical seizure activity [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/7\" class=\"abstract_t\">7</a>]. Coadministration of an opioid or benzodiazepine adjuvant agent during induction of anesthesia typically attenuates myoclonus (see <a href=\"#H240924670\" class=\"local\">'Opioids'</a> below and <a href=\"#H818607874\" class=\"local\">'Midazolam'</a> below). However, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> is often selected to induce anesthesia in patients with hemodynamic instability, and these adjuvant agents are usually avoided or the dose is reduced in such patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/41-44\" class=\"abstract_t\">41-44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of any analgesic effect. <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> does not blunt the sympathetic stress response to noxious stimulation of the upper airway during laryngoscopy and intubation. If this is a concern in patients with cardiovascular disease or elevated ICP, prior administration of an opioid <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> may attenuate the stress response that would otherwise result in tachycardia and hypertension. (See <a href=\"#H240924670\" class=\"local\">'Opioids'</a> below and <a href=\"#H1973711502\" class=\"local\">'Lidocaine'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild increase in airway resistance [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transient acute adrenal insufficiency. Although <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> transiently inhibits cortisol biosynthesis, the preponderance of evidence suggests that this is not harmful in most clinical settings and does not preclude its use [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/45-49\" class=\"abstract_t\">45-49</a>]. To avoid further suppression of cortisol, we do not administer multiple bolus doses or infusions of etomidate. In patients with suspected adrenal insufficiency, such as those on chronic glucocorticoid therapy, the clinician must weigh the risk of further cortisol suppression caused by etomidate against the risk of hemodynamic instability that may be caused by alternative induction agents. </p><p/><p class=\"bulletIndent1\">Following a single induction dose of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, reversible inhibition of 11-beta-hydroxylase (which converts 11-deoxycortisol to cortisol) causes adrenocortical suppression lasting &lt;24 hours in both healthy and critically ill patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/45-54\" class=\"abstract_t\">45-54</a>]. Although cortisol plasma concentrations may not appropriately rise in response to surgical stimulation after etomidate administration, concentrations do not necessarily fall below the normal range, and the clinical significance of this finding is uncertain [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/52,53\" class=\"abstract_t\">52,53</a>]. </p><p/><p class=\"bulletIndent1\">Limited safety data exist for anesthetic induction with <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> in surgical settings. One retrospective study in patients undergoing anesthesia for noncardiac surgery reported that etomidate induction in 2144 patients was associated with increased 30-day mortality compared with 5233 propensity-matched patients who received <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> for induction (odds ratio [OR] 2.5, 98% CI 1.9-3.4) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/55\" class=\"abstract_t\">55</a>]. However, this nonrandomized study may have important confounding covariates. In particular, etomidate is often selected for induction in patients who are critically ill, and this may have accounted for the study's findings. Retrospective studies in patients undergoing cardiac surgery have noted no increase in mortality after use of etomidate for anesthetic induction versus any other induction agent [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/56,57\" class=\"abstract_t\">56,57</a>]. One prospective study in patients undergoing coronary artery bypass grafting (CABG) noted no differences in mortality, perioperative vasopressor requirements, time to extubation, or length of intensive care unit (ICU) stay with etomidate compared with propofol use for induction [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"bulletIndent1\">In critically ill patients undergoing emergency tracheal intubation, a 2015 systematic review of eight randomized trials concluded that <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> was not associated with increased mortality compared with any other induction agent (OR 1.17, 95% CI 0.86-1.60) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/50\" class=\"abstract_t\">50</a>]. Also, there is no definitive evidence that a single dose of etomidate increases mortality in critically ill patients diagnosed with sepsis [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/58\" class=\"abstract_t\">58</a>]. However, use of etomidate in patients with frank septic shock is controversial and we usually select an alternative anesthetic induction agent in this circumstance. (See <a href=\"topic.htm?path=intraoperative-management-of-shock-in-adults#H2106070480\" class=\"medical medical_review\">&quot;Intraoperative management of shock in adults&quot;, section on 'Septic shock'</a>.)</p><p/><p class=\"bulletIndent1\">If <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> has been used in a septic patient who subsequently develops refractory hypotension, a stress dose of a glucocorticoid should be administered (eg, intravenous [IV] <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> 100 mg or <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> 4 mg) (see <a href=\"topic.htm?path=glucocorticoid-therapy-in-septic-shock\" class=\"medical medical_review\">&quot;Glucocorticoid therapy in septic shock&quot;</a>). However, we do not administer prophylactic glucocorticoids in other settings. There was no association between intraoperative steroid administration and mortality after anesthetic induction with etomidate in a retrospective study of 582 patients who received intraoperative steroids (typically dexamethasone at a median dose of 6 mg) compared with 1023 propensity-matched patients who received no steroids after induction with etomidate [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/59\" class=\"abstract_t\">59</a>]. </p><p/><p class=\"headingAnchor\" id=\"H242460226\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types, including opioids, benzodiazepines, and volatile anesthetics, may produce synergistic anesthetic effects [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below and <a href=\"#H4201415421\" class=\"local\">'Dosing'</a> below.)</p><p class=\"headingAnchor\" id=\"H3348275065\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> has a very rapid speed of onset, similar to <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/60\" class=\"abstract_t\">60</a>]. The half-life of equilibration <span class=\"nowrap\">(t1/2</span> keo) between plasma and effect site (the brain) is 1.6 minutes [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/61\" class=\"abstract_t\">61</a>].</p><p><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> has a short duration of action (3 to 12 minutes) because it is rapidly redistributed from the brain to other tissues. The volume of distribution is 2.5 to 4.5 <span class=\"nowrap\">L/kg</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/60-62\" class=\"abstract_t\">60-62</a>]. Clearance of etomidate is high (18 to 25 <span class=\"nowrap\">mL/kg/minute)</span>. Terminal elimination half-life is three to five hours. The main route of metabolism is ester hydrolysis in the liver, and the metabolites are pharmacologically inactive.</p><p class=\"headingAnchor\" id=\"H4201415421\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The induction dose of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> for general anesthesia is 0.15 to 0.3 <span class=\"nowrap\">mg/kg</span> (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/63\" class=\"abstract_t\">63</a>]. After induction, repeated bolus doses of etomidate should <strong>NOT</strong> be administered so that further inhibition of cortisol biosynthesis is avoided. (See <a href=\"#H262499028\" class=\"local\">'Adverse effects'</a> above.)</p><p>Although the dose of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> is not typically adjusted to avoid hemodynamic side effects, it is prudent to reduce the initial dose in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coadministration of one or more adjuvant anesthetic agents [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe hypotension or shock; suggested dose is 0.1 to 0.15 <span class=\"nowrap\">mg/kg</span>. (As discussed above, the use of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> in patients with known septic shock is controversial.) (See <a href=\"topic.htm?path=intraoperative-management-of-shock-in-adults#H1077875245\" class=\"medical medical_review\">&quot;Intraoperative management of shock in adults&quot;, section on 'Induction'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2269465\"><span class=\"h1\">KETAMINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> may be selected to induce anesthesia in hypotensive patients or those likely to develop hypotension during induction due to hypovolemia, hemorrhage, sepsis, or severe cardiovascular compromise. Ketamine typically increases blood pressure (BP), heart rate (HR), and cardiac output (CO) by increasing sympathetic tone (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/64-66\" class=\"abstract_t\">64-66</a>].</p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is structurally similar to phencyclidine and produces dissociative anesthesia (profound analgesia while appearing disconnected from surroundings) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/67\" class=\"abstract_t\">67</a>]. The term &quot;dissociative&quot; is also used to describe the electroencephalographic (EEG) effects of ketamine because EEG activity in the hippocampus is dissociated from that in the thalamo-neocortical system.</p><p>The primary mechanism of action is noncompetitive antagonism of glutamate at the N-methyl-D-aspartate (NMDA) receptor-cation channel complex, causing neuroinhibition and anesthesia [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/68\" class=\"abstract_t\">68</a>]. Also, <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> excites opioid receptors within the insular cortex, putamen, and thalamus, thereby producing analgesia.</p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is the only induction agent that stimulates catecholamine receptors, producing increases in BP, HR, contractility, pulmonary arterial pressure (PAP), and cerebral blood flow (CBF) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/69-71\" class=\"abstract_t\">69-71</a>]. Also, ketamine reduces vasodilation by decreasing the production of vascular nitric oxide [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H887839396\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> has the following advantages (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increases sympathetic tone with consequent increases in BP, HR, and CO in most patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/64-66\" class=\"abstract_t\">64-66</a>]. However, these increases do not occur if presynaptic catecholamine stores are depleted [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/73\" class=\"abstract_t\">73</a>]. (See <a href=\"#H2269513\" class=\"local\">'Adverse effects'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchodilatory properties. <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is useful in patients with bronchospasm <span class=\"nowrap\">and/or</span> asthma [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/74,75\" class=\"abstract_t\">74,75</a>]. (See <a href=\"topic.htm?path=anesthesia-for-adult-patients-with-asthma#H1234674358\" class=\"medical medical_review\">&quot;Anesthesia for adult patients with asthma&quot;, section on 'Anesthetic agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maintains airway reflexes and respiratory drive. <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is useful when maintenance of spontaneous respiration is desirable [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/65,76\" class=\"abstract_t\">65,76</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Profound analgesic properties, even in sub-hypnotic doses. Intraoperative administration of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> reduces postoperative opioid consumption in patients with chronic pain, opioid tolerance, or hyperalgesia [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/77-80\" class=\"abstract_t\">77-80</a>]. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H88573074\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Ketamine'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid onset and recovery after intravenous (IV) administration, similar to <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alternative routes of administration, if necessary. In rare cases when IV access is impractical or inadvertently lost during induction (eg, in a severely agitated uncooperative patient), intramuscular (IM) injection is feasible. For children, oral or rectal administration is also possible.</p><p/><p class=\"headingAnchor\" id=\"H2269513\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> has the following potential adverse effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"headingAnchor\" id=\"H3402618051\"><span class=\"h3\">Cardiovascular effects</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with ischemic heart disease, sympathomimetic effects that increase HR and BP may be detrimental due to imbalance between myocardial oxygen supply and demand [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/81\" class=\"abstract_t\">81</a>]. (See <a href=\"topic.htm?path=anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease#H2200606372\" class=\"medical medical_review\">&quot;Anesthesia for noncardiac surgery in patients with ischemic heart disease&quot;, section on 'Induction'</a> and <a href=\"topic.htm?path=anesthesia-for-adult-patients-with-hypertension\" class=\"medical medical_review\">&quot;Anesthesia for adult patients with hypertension&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with pulmonary hypertension or right heart dysfunction, sympathomimetic effects that increase PAP may be detrimental [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/81\" class=\"abstract_t\">81</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a hypertensive patient, sympathomimetic effects may further increase BP. <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is never administered to a patient with pheochromocytoma as it might precipitate severe hypertension, as well as tachycardia and arrhythmias. (See <a href=\"topic.htm?path=anesthesia-for-the-adult-with-pheochromocytoma#H110029640\" class=\"medical medical_review\">&quot;Anesthesia for the adult with pheochromocytoma&quot;, section on 'Medications to avoid'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intrinsic mild myocardial depressant properties that are normally overcome by increased sympathetic tone, but may become apparent in the critically ill patient with depleted catecholamine reserves (eg, profound hypovolemic, septic, or cardiogenic shock) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/73\" class=\"abstract_t\">73</a>]. Since these depressant effects are dose-related, induction doses are reduced in a patient with profound hypotension (mean arterial pressure [MAP] &lt;50 mmHg) or shock. (See <a href=\"#H1177223154\" class=\"local\">'Dosing'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H3058808067\"><span class=\"h3\">Neurologic effects</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Psychotomimetic effects that include hallucinations, nightmares, and vivid dreams during and shortly after emergence from anesthesia [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/82,83\" class=\"abstract_t\">82,83</a>]. Prior administration of a benzodiazepine may minimize these effects [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/84\" class=\"abstract_t\">84</a>]. (See <a href=\"#H818607874\" class=\"local\">'Midazolam'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible increased cerebral metabolism with increased sympathetic stimulation [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/85\" class=\"abstract_t\">85</a>]. However, some clinical studies suggest <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> does not significantly interfere with cerebral metabolism [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/69,86,87\" class=\"abstract_t\">69,86,87</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sympathomimetic effects that increase CBF and intracranial pressure (ICP) in spontaneously breathing patients. (See <a href=\"topic.htm?path=anesthesia-for-craniotomy#H8564106\" class=\"medical medical_review\">&quot;Anesthesia for craniotomy&quot;, section on 'Induction of anesthesia'</a> and <a href=\"topic.htm?path=anesthesia-for-patients-with-acute-traumatic-brain-injury#H128065263\" class=\"medical medical_review\">&quot;Anesthesia for patients with acute traumatic brain injury&quot;, section on 'Choice of anesthetic agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unique EEG effects that may result in misinterpretation of processed EEG values (eg, the bispectral index [BIS]). (See <a href=\"topic.htm?path=neuromonitoring-in-surgery-and-anesthesia#H601409817\" class=\"medical medical_review\">&quot;Neuromonitoring in surgery and anesthesia&quot;, section on 'Intravenous agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible neurotoxicity. Animal studies have reported mixed results for potential neurotoxic versus neuroprotective effects of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/88-90\" class=\"abstract_t\">88-90</a>].</p><p/><p class=\"headingAnchor\" id=\"H4195246664\"><span class=\"h3\">Other effects</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> increases salivation and upper airway secretions, this side effect is not relevant during induction of general anesthesia.</p><p/><p class=\"headingAnchor\" id=\"H1385138965\"><span class=\"h2\">Drug-drug interactions</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is avoided if cocaine use is suspected. Cocaine's cardiovascular toxicity may be potentiated by the sympathomimetic effects of ketamine and lead to myocardial ischemia, arrhythmias, and pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/91\" class=\"abstract_t\">91</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients taking a tricyclic antidepressant, a low initial induction dose of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> is administered (eg, 1 <span class=\"nowrap\">mg/kg)</span> because both agents inhibit norepinephrine reuptake [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/92\" class=\"abstract_t\">92</a>]. (See <a href=\"#H1177223154\" class=\"local\">'Dosing'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coadministration of a volatile anesthetic agent during induction may result in synergistic anesthetic effects. The induction dose is reduced in this circumstance [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H1177223154\" class=\"local\">'Dosing'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H3610684087\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> has a very rapid speed of onset, with a half-life of equilibration <span class=\"nowrap\">(t1/2</span> keo) between plasma and effect site (the brain) that is &lt;1 minute [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/93\" class=\"abstract_t\">93</a>].</p><p>The primary metabolite of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> is norketamine, which has significant pharmacodynamic effects that are similar to those of ketamine but with one-tenth to one-third of ketamine's potency [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/94\" class=\"abstract_t\">94</a>]. Norketamine contributes to total time until return of consciousness after an induction dose (9 to 20 minutes) as well as the analgesic effects, which last longer than the anesthetic effects [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/95,96\" class=\"abstract_t\">95,96</a>].</p><p>The volume of distribution is approximately 3 <span class=\"nowrap\">L/kg</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/95,96\" class=\"abstract_t\">95,96</a>]. Clearance is similar to liver blood flow (15 to 20 <span class=\"nowrap\">mL/kg/minute)</span>. Neither renal nor moderate hepatic dysfunction has a clinically significant effect on <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> clearance. The terminal elimination half-life is two to three hours.</p><p>After intramuscular (IM) administration of 6 <span class=\"nowrap\">mg/kg</span> in adults, peak plasma concentrations occur after 15 to 30 minutes and are similar to concentrations after IV administration of 2 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/97\" class=\"abstract_t\">97</a>]. Due to variable absorption from muscle tissue, clinical duration of action may be significantly longer after IM administration compared with IV administration [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/97\" class=\"abstract_t\">97</a>].</p><p class=\"headingAnchor\" id=\"H1177223154\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The IV induction dose of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> for general anesthesia is 1 to 2 <span class=\"nowrap\">mg/kg</span> IV (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). The IM induction dose is 4 to 6 <span class=\"nowrap\">mg/kg</span>.</p><p>The dose of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> is not typically adjusted to avoid hemodynamic side effects. Also, no dose reduction is necessary when ketamine is coadministered with other adjuvant agents (see <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below). These agents have only additive or infra-additive (antagonistic) effects when combined with ketamine, rather than synergistic effects [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>].</p><p>However, a lower initial dose is prudent in the following circumstances (see <a href=\"#H1385138965\" class=\"local\">'Drug-drug interactions'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic use of a tricyclic antidepressant, since both drugs inhibit norepinephrine reuptake (suggested dose is 1 <span class=\"nowrap\">mg/kg)</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/92\" class=\"abstract_t\">92</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe hypotension or shock in a patient whose catecholamine reserves may be depleted (eg, profound hypovolemic, septic, or cardiogenic shock); suggested dose is 0.5 to 1 <span class=\"nowrap\">mg/kg</span>. (See <a href=\"topic.htm?path=intraoperative-management-of-shock-in-adults#H1077875245\" class=\"medical medical_review\">&quot;Intraoperative management of shock in adults&quot;, section on 'Induction'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H181245995\"><span class=\"h1\">METHOHEXITAL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">Methohexital</a> is an oxybarbiturate used as an induction agent for patients undergoing electroconvulsive therapy (ECT) because it activates seizure foci (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). (See <a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults#H10\" class=\"medical medical_review\">&quot;Technique for performing electroconvulsive therapy (ECT) in adults&quot;, section on 'Anesthesia technique'</a>.)</p><p>Similar to <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, barbiturates facilitate inhibitory neurotransmission by enhancing gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor function. Barbiturates also directly activate chloride channels, thereby mimicking the action of GABA. Furthermore, excitatory neurotransmission is inhibited by barbiturates via glutamate and nicotinic acetylcholine receptors.</p><p class=\"headingAnchor\" id=\"H3311352297\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">methohexital</a> activates seizure foci, it is an ideal induction drug for patients undergoing ECT.</p><p class=\"headingAnchor\" id=\"H356478373\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">Methohexital</a> has the following potential adverse effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent hypotension due to venodilation and depression of myocardial contractility. This results in decreased blood pressure (BP) and cardiac output (CO). Although the decrease in BP is less than that caused by an induction dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, the induction dose of a barbiturate is reduced in older patients and others prone to develop hypotension. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183400993\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Sedative-hypnotics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increases in heart rate (HR) in response to hypotension because baroreceptor reflexes remain intact. Increased HR, in combination with decreased BP, may detrimentally unbalance myocardial oxygen supply versus demand in patients with ischemic heart disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent respiratory depression (decreases in respiratory rate, tidal volume, and ventilatory response to hypoxia and hypercarbia). Apnea may result.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pain on injection in up to 60 percent of patients [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/98\" class=\"abstract_t\">98</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Involuntary myoclonic movements and hiccups.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute exacerbation of acute intermittent porphyria by inducing hepatic enzymes involved in heme biosynthesis [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/99\" class=\"abstract_t\">99</a>]. <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">Methohexital</a>, like other barbiturates, is contraindicated in these patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare anaphylactic reactions. (See <a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management#H9\" class=\"medical medical_review\">&quot;Perioperative anaphylaxis: Clinical manifestations, etiology, and management&quot;, section on 'Hypnotic induction agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2613619630\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types, including opioids, benzodiazepines, and volatile anesthetics, may produce synergistic anesthetic effects. Thus, reduction of the <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">methohexital</a> dose is prudent. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> below and <a href=\"#H3270637583\" class=\"local\">'Dosing'</a> below.)</p><p class=\"headingAnchor\" id=\"H2621093711\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">Methohexital</a> has a rapid onset (10 to 30 seconds), a volume of distribution of approximately 2 <span class=\"nowrap\">L/kg,</span> and a clearance that is higher than thiopental but somewhat lower than other sedative-hypnotic induction agents (11 <span class=\"nowrap\">mL/kg/minute)</span>. The elimination half-life is four hours.</p><p class=\"headingAnchor\" id=\"H3270637583\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The induction dose of <a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">methohexital</a> is 1.5 <span class=\"nowrap\">mg/kg</span>. Dose-dependent hypotension is avoided by reducing the initial dose and titrating methohexital in increments, particularly in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Older age (suggested dose is 1 <span class=\"nowrap\">mg/kg)</span>. Dose reduction is prudent due to changes in pharmacodynamics, as well as changes in clearance and central volume of distribution [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183400993\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Sedative-hypnotics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types due to synergistic effects.</p><p/><p class=\"headingAnchor\" id=\"H2272654275\"><span class=\"h1\">ADJUVANT AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adjuvant intravenous (IV) agents are often used to supplement the effects of the primary anesthetic induction agent. The most common adjuvants are an opioid, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, <span class=\"nowrap\">and/or</span> a benzodiazepine (usually <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>) (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>).</p><p>Many patients receive more than one adjuvant agent during induction, particularly if endotracheal intubation is planned, in order to reduce the dose of sedative-hypnotic as well as blunt airway reflexes and the sympathetic stress response to laryngoscopy and tracheal intubation. There is no evidence from randomized trials to support use of a particular drug combination. Choices and doses of agents are determined by patient-specific factors, including age and comorbidities.</p><p>Administration of adjuvant agents is usually reduced or eliminated in older patients and in those with impaired renal <span class=\"nowrap\">and/or</span> hepatic function, as well as in those with actual or potential hemodynamic instability. (See <a href=\"#H4070595924\" class=\"local\">'Dosing considerations'</a> above.)</p><p class=\"headingAnchor\" id=\"H240924670\"><span class=\"h2\">Opioids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opioids are the most commonly used adjuvant agents during induction of general anesthesia (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>). Although opioids bind to specific receptors in the brain, spinal cord, and peripheral neurons, the agents used during induction of anesthesia bind primarily to mu receptors. (See <a href=\"topic.htm?path=perioperative-uses-of-intravenous-opioids-in-adults\" class=\"medical medical_review\">&quot;Perioperative uses of intravenous opioids in adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Advantages during induction</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suppression of airway reflexes that result in coughing <span class=\"nowrap\">and/or</span> bronchospasm during laryngoscopy and intubation [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/100\" class=\"abstract_t\">100</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Attenuation of the stress response to laryngoscopy and endotracheal intubation that would otherwise result in tachycardia and hypertension [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/101-103\" class=\"abstract_t\">101-103</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reduction of pain caused by IV injection of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, or muscle relaxants [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/23-27\" class=\"abstract_t\">23-27</a>], although reduction may be optimally achieved with <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> or a combination of lidocaine plus an opioid [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Supplementation of sedation to reduce the dose requirement of the selected sedative-hypnotic induction agent [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/104-108\" class=\"abstract_t\">104-108</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adverse effects </strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Exacerbation of the hypotensive effects of sedative-hypnotic induction agents.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Respiratory depression <span class=\"nowrap\">and/or</span> apnea, a side effect of all commonly used opioids. If laryngeal mask insertion with subsequent spontaneous ventilation is planned, some clinicians will omit opioid administration during the induction sequence to avoid a period of postinduction apnea.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Other adverse effects may become evident in the postoperative period when large or additional opioid doses are administered, including nausea and vomiting, ileus, constipation, urinary retention, pruritus, delirium, acute tolerance, and hyperalgesia. These effects are discussed separately. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing</strong> &ndash; Opioid medications produce analgesia and sedation in a dose-dependent manner. Dose reduction is prudent in selected patients:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Older adults, since potency may be increased by age-related changes in pharmacokinetics and pharmacodynamics. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183401005\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Coadministration with agents from different classes because of synergistic effects of these combinations (eg, sedative-hypnotics such as <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, benzodiazepines such as <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, or volatile inhalation anesthetic agent) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with actual or potential hemodynamic instability, since opioids may exacerbate hypotension or bradycardia.</p><p/><p class=\"bulletIndent1\">Typical doses of the opioid agents commonly used during induction of general anesthesia (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>) are noted in the table (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>).</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> may be used in selected cases requiring rapid sequence intubation if <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> is contraindicated and the prolonged duration of a nondepolarizing neuromuscular blocking agent (NMBA) is undesirable. The remifentanil intubation technique is described separately. (See <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H107498333\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Remifentanil intubation'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1973711502\"><span class=\"h2\">Lidocaine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">Lidocaine</a> is often used to reduce the pain of injection of other induction agents and to suppress airway reflexes during induction of general anesthesia (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Advantages during induction</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suppresses the cough reflex during laryngoscopy and intubation [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/109-118\" class=\"abstract_t\">109-118</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reduces incidence of bronchospasm by reducing airway responsiveness to noxious stimuli and to drugs that cause bronchospasm, despite causing an increase in airway tone [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/119-121\" class=\"abstract_t\">119-121</a>]. (See <a href=\"topic.htm?path=anesthesia-for-adult-patients-with-asthma#H607404411\" class=\"medical medical_review\">&quot;Anesthesia for adult patients with asthma&quot;, section on 'Intravenous agents'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reduces pain caused by IV injection of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, or muscle relaxants when administered into the same vein. Due to its local anesthetic effect, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> is more effective for this purpose than opioids [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/22-27\" class=\"abstract_t\">22-27</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Supplements sedation to reduce the dose requirement of the selected IV sedative-hypnotic induction agent [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/122\" class=\"abstract_t\">122</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adverse effects</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Accentuates the hypotensive effects of sedative-hypnotic induction agents.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>May increase the ventricular rate in patients with atrial fibrillation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&ndash; Dose is based on the indication:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For reduction of pain on injection due to <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> or another agent, 20 to 30 mg is administered into the same vein.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For attenuation of airway responses to laryngoscopy and endotracheal intubation, 1 to 1.5 <span class=\"nowrap\">mg/kg</span> is administered as a bolus.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Dose is reduced to 0.5 to 1 <span class=\"nowrap\">mg/kg</span> in older adults.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Dose is reduced to &le;0.5 <span class=\"nowrap\">mg/kg</span> or eliminated in patients with hemodynamic instability.</p><p/><p class=\"headingAnchor\" id=\"H818607874\"><span class=\"h2\">Midazolam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> is often used shortly before (within 30 to 60 minutes) induction as a premedicant or during induction as an adjuvant agent, especially in anxious, fully awake patients. The primary mechanism of action is activation of the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor, thereby inhibiting neurotransmission [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/123\" class=\"abstract_t\">123</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Advantages before and during induction </strong>&ndash; <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam</a> has dose-dependent properties that include (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/124\" class=\"abstract_t\">124</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Anxiolysis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Amnesia</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Anticonvulsant properties</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Sedation, which supplements and reduces dose requirement of the selected IV sedative-hypnotic induction agent [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/106\" class=\"abstract_t\">106</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adverse effects</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Mild systemic vasodilation and decreased cardiac output (CO), with consequent decrease in blood pressure (BP). This may be pronounced in patients with preexisting hypovolemia or vasodilation [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/124\" class=\"abstract_t\">124</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dose-dependent respiratory depression, which may be problematic if an opioid is concurrently administered. Minute ventilation and the ventilatory response to carbon dioxide (CO<sub>2</sub>) decrease; apnea may occur with higher doses (&ge;0.15 <span class=\"nowrap\">mg/kg)</span> [<a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/124,125\" class=\"abstract_t\">124,125</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&mdash; A typical dose for younger, anxious adults is 1 to 4 mg administered in 1-mg increments.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dose is eliminated or reduced to 0.5 to 2 mg in older adults, administered in 0.5-mg increments.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dose is eliminated or reduced to 0.5 to 1 mg in patients with actual or potential hemodynamic instability.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dose is eliminated for some enhanced recovery after surgery (ERAS) protocols.</p><p/><p class=\"headingAnchor\" id=\"H288547807\"><span class=\"h1\">SELECTION OF INDUCTION AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Induction of general anesthesia may be accomplished using either an intravenous (IV) or inhalational technique, although combinations of agents are common. The selection of an induction technique for general anesthesia is discussed separately. (See <a href=\"topic.htm?path=general-anesthesia-induction#H295889468\" class=\"medical medical_review\">&quot;General anesthesia: Induction&quot;, section on 'Selection of induction technique'</a>.)</p><p>The choice of an induction agent for rapid sequence intubation in the operating room and elsewhere is discussed separately. (See <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H1078269059\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Induction agents'</a> and <a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room#H14\" class=\"medical medical_review\">&quot;Induction agents for rapid sequence intubation in adults outside the operating room&quot;, section on 'Choice of induction agent'</a>.)</p><p class=\"headingAnchor\" id=\"H3792454773\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial doses of intravenous (IV) sedative-hypnotic and adjuvant agents selected to induce general anesthesia are individualized; additional doses are titrated to effect. Factors affecting dosing include individual patient variations in pharmacodynamics and pharmacokinetics, dose-dependent adverse effects (eg, hypotension), and coadministration of adjuvant drugs. (See <a href=\"#H4070595924\" class=\"local\">'Dosing considerations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is the IV induction agent of choice for most patients because of its rapid onset and offset, beneficial properties, and relatively benign side effects (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). (See <a href=\"#H2269410\" class=\"local\">'Propofol'</a> above.)</p><p/><p class=\"bulletIndent1\">Advantages of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> include antiemetic, antipruritic, bronchodilatory, and anticonvulsant properties, suitability for patients with renal <span class=\"nowrap\">and/or</span> hepatic insufficiency, and ability to decrease intracranial pressure (ICP). (See <a href=\"#H2657717339\" class=\"local\">'Advantages'</a> above.)</p><p/><p class=\"bulletIndent1\">Potential adverse effects of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> include dose-dependent hypotension and respiratory depression, pain on injection, and contamination risk. (See <a href=\"#H2269447\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> is often selected in patients with hemodynamic instability due to any cause, because it does not change blood pressure (BP), cardiac output (CO), or heart rate (HR) (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). (See <a href=\"#H307136729\" class=\"local\">'Etomidate'</a> above.)</p><p/><p class=\"bulletIndent1\">Advantages of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> include its hemodynamic stability, anticonvulsant properties, and ability to decrease ICP. (See <a href=\"#H3248597381\" class=\"local\">'Advantages'</a> above.)</p><p/><p class=\"bulletIndent1\">Potential adverse effects of <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> include transient acute adrenal insufficiency, higher incidence of nausea and vomiting than other induction agents, pain on injection, absence of analgesic effect, involuntary myoclonic movements, and mild increases in airway resistance. (See <a href=\"#H262499028\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> may be selected to induce anesthesia in patients with actual or potential severe hypotension because administration typically increases BP, HR, and CO (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). (See <a href=\"#H2269465\" class=\"local\">'Ketamine'</a> above.)</p><p/><p class=\"bulletIndent1\">Additional advantages of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> include bronchodilation, profound analgesic properties, maintenance of airway reflexes and respiratory drive, and an intramuscular (IM) route of administration if IV access is not feasible. (See <a href=\"#H887839396\" class=\"local\">'Advantages'</a> above.)</p><p/><p class=\"bulletIndent1\">Potential adverse cardiovascular effects of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> include increased HR, BP, CO, and pulmonary arterial pressure (PAP) that may be detrimental in patients with ischemic heart disease or systemic or pulmonary hypertension. Rarely, its mild direct myocardial depressant effects are detrimental for patients with depleted catecholamine reserves (eg, hypovolemic, septic, or cardiogenic shock). (See <a href=\"#H3402618051\" class=\"local\">'Cardiovascular effects'</a> above.)</p><p/><p class=\"bulletIndent1\">Potential adverse neurologic effects include a high incidence of psychotomimetic effects, increases in cerebral blood flow (CBF) and ICP, and unique electroencephalographic (EEG) effects that may lead to misinterpretation of processed EEG values. (See <a href=\"#H3058808067\" class=\"local\">'Neurologic effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=methohexital-drug-information\" class=\"drug drug_general\">Methohexital</a> is primarily used as an induction agent for patients undergoing electroconvulsive therapy (ECT) because it activates seizure foci (<a href=\"image.htm?imageKey=ANEST%2F102350\" class=\"graphic graphic_table graphicRef102350 \">table 1</a>). (See <a href=\"#H181245995\" class=\"local\">'Methohexital'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adjuvant medications such as an opioid, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> are typically administered during induction to blunt the sympathetic stress response and cough reflex during laryngoscopy and intubation, to minimize pain due to injection of the anesthetic induction agents, and to supplement sedation (<a href=\"image.htm?imageKey=ANEST%2F106541\" class=\"graphic graphic_table graphicRef106541 \">table 3</a>). Dose reduction of the sedative-hypnotic induction agent is prudent because of synergistic effects when these agents are combined. (See <a href=\"#H2272654275\" class=\"local\">'Adjuvant agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The selection of an induction technique for general anesthesia and for rapid sequence intubation is discussed separately. (See <a href=\"topic.htm?path=general-anesthesia-induction#H295889468\" class=\"medical medical_review\">&quot;General anesthesia: Induction&quot;, section on 'Selection of induction technique'</a> and <a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room#H14\" class=\"medical medical_review\">&quot;Induction agents for rapid sequence intubation in adults outside the operating room&quot;, section on 'Choice of induction agent'</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/1\" class=\"nounderline abstract_t\">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li class=\"breakAll\">Bowdle TA. Can we prevent recall during anesthesia?. In: Evidence-Based Practice of Anesthesiology, 3rd ed, Fleisher L (Ed), Elsevier, Philadelphia 2013.</li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/3\" class=\"nounderline abstract_t\">Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/4\" class=\"nounderline abstract_t\">Eames WO, Rooke GA, Wu RS, Bishop MJ. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Anesthesiology 1996; 84:1307.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/5\" class=\"nounderline abstract_t\">Conti G, Ferretti A, Tellan G, et al. Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus. Intensive Care Med 1993; 19:305.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/6\" class=\"nounderline abstract_t\">Pizov R, Brown RH, Weiss YS, et al. Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology 1995; 82:1111.</a></li><li class=\"breakAll\">Paul F. White and Matthew R. Eng. Intravenous Anesthetics. In: Clinical Anesthesia, Seventh, Paul G. Barash (Ed), Lippincott Williams &amp;  Wilkins, Philadelphia 2013. p.478-500.</li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/8\" class=\"nounderline abstract_t\">Pinaud M, Lelausque JN, Chetanneau A, et al. Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma. Anesthesiology 1990; 73:404.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/9\" class=\"nounderline abstract_t\">Shafer SL. Advances in propofol pharmacokinetics and pharmacodynamics. J Clin Anesth 1993; 5:14S.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/10\" class=\"nounderline abstract_t\">Gray PA, Park GR, Cockshott ID, et al. Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation. Xenobiotica 1992; 22:105.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/11\" class=\"nounderline abstract_t\">Smith I, White PF, Nathanson M, Gouldson R. Propofol. An update on its clinical use. Anesthesiology 1994; 81:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/12\" class=\"nounderline abstract_t\">Takizawa D, Hiraoka H, Nakamura K, et al. Propofol concentrations during the anhepatic phase of living-related donor liver transplantation. Clin Pharmacol Ther 2004; 76:648.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/13\" class=\"nounderline abstract_t\">Takizawa D, Hiraoka H, Goto F, et al. Human kidneys play an important role in the elimination of propofol. Anesthesiology 2005; 102:327.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/14\" class=\"nounderline abstract_t\">Kuipers JA, Boer F, Olieman W, et al. First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. Anesthesiology 1999; 91:1780.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/15\" class=\"nounderline abstract_t\">Reekers M, Boer F, Vuyk J. Basic concepts of recirculatory pharmacokinetic modelling. Adv Exp Med Biol 2003; 523:19.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/16\" class=\"nounderline abstract_t\">Shafer SL. Shock values. Anesthesiology 2004; 101:567.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/17\" class=\"nounderline abstract_t\">Scheffer GJ, Ten Voorde BJ, Karemaker JM, et al. Effects of thiopentone, etomidate and propofol on beat-to-beat cardiovascular signals in man. Anaesthesia 1993; 48:849.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/18\" class=\"nounderline abstract_t\">Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/19\" class=\"nounderline abstract_t\">Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100:610.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/20\" class=\"nounderline abstract_t\">Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology 2005; 103:20.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/21\" class=\"nounderline abstract_t\">Masuda T, Tomiyama Y, Kitahata H, et al. Propofol inhibits volume-sensitive chloride channels in human coronary artery smooth muscle cells. Anesth Analg 2003; 97:657.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/22\" class=\"nounderline abstract_t\">Euasobhon P, Dej-Arkom S, Siriussawakul A, et al. Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults. Cochrane Database Syst Rev 2016; 2:CD007874.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/23\" class=\"nounderline abstract_t\">Picard P, Tram&egrave;r MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg 2000; 90:963.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/24\" class=\"nounderline abstract_t\">El-Radaideh KM. [Effect of pretreatment with lidocaine, intravenous paracetamol and lidocaine-fentanyl on propofol injection pain. Comparative study. Rev Bras Anestesiol 2007; 57:32.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/25\" class=\"nounderline abstract_t\">Prabhakar H, Singh GP, Ali Z, et al. Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain on injection in children and adults. Cochrane Database Syst Rev 2016; 2:CD009346.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/26\" class=\"nounderline abstract_t\">Aouad MT, Siddik-Sayyid SM, Al-Alami AA, Baraka AS. Multimodal analgesia to prevent propofol-induced pain: pretreatment with remifentanil and lidocaine versus remifentanil or lidocaine alone. Anesth Analg 2007; 104:1540.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/27\" class=\"nounderline abstract_t\">Rahman Al-Refai A, Al-Mujadi H, Petrova Ivanova M, et al. Prevention of pain on injection of propofol: a comparison of remifentanil with alfentanil in children. Minerva Anestesiol 2007; 73:219.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/28\" class=\"nounderline abstract_t\">Muller AE, Huisman I, Roos PJ, et al. Outbreak of severe sepsis due to contaminated propofol: lessons to learn. J Hosp Infect 2010; 76:225.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/29\" class=\"nounderline abstract_t\">Asserh&oslash;j LL, Mosbech H, Kr&oslash;igaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut&dagger;. Br J Anaesth 2016; 116:77.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/30\" class=\"nounderline abstract_t\">Vinik HR, Bradley EL Jr, Kissin I. Triple anesthetic combination: propofol-midazolam-alfentanil. Anesth Analg 1994; 78:354.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/31\" class=\"nounderline abstract_t\">Absalom AR, Mani V, De Smet T, Struys MM. Pharmacokinetic models for propofol--defining and illuminating the devil in the detail. Br J Anaesth 2009; 103:26.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/32\" class=\"nounderline abstract_t\">Khan KS, Hayes I, Buggy DJ. Pharmacology of anaesthetic agents I: intravenous induction agents. Contin Educ Anaesth Crit Care Pain 2014; 14:100.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/33\" class=\"nounderline abstract_t\">Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76:334.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/34\" class=\"nounderline abstract_t\">Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 1992; 76:327.</a></li><li class=\"breakAll\">Drug insert for propofol: FDA-approved dose http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019627s046lbl.pdf (Accessed on April 26, 2016).</li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/36\" class=\"nounderline abstract_t\">Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS. Pharmacokinetics of propofol (diprivan) in elderly patients. Br J Anaesth 1988; 60:146.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/37\" class=\"nounderline abstract_t\">Das S, Forrest K, Howell S. General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent. Drugs Aging 2010; 27:265.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/38\" class=\"nounderline abstract_t\">Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011; 114:695.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/39\" class=\"nounderline abstract_t\">Holdcroft A, Morgan M, Whitwam JG, Lumley J. Effect of dose and premedication on induction complications with etomidate. Br J Anaesth 1976; 48:199.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/40\" class=\"nounderline abstract_t\">Fruergaard K, Jenstrup M, Schierbeck J, Wiberg-J&oslash;rgensen F. Total intravenous anaesthesia with propofol or etomidate. Eur J Anaesthesiol 1991; 8:385.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/41\" class=\"nounderline abstract_t\">H&uuml;ter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion. Anesth Analg 2007; 105:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/42\" class=\"nounderline abstract_t\">Hueter L, Schwarzkopf K, Simon M, et al. Pretreatment with sufentanil reduces myoclonus after etomidate. Acta Anaesthesiol Scand 2003; 47:482.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/43\" class=\"nounderline abstract_t\">Stockham RJ, Stanley TH, Pace NL, et al. Fentanyl pretreatment modifies anaesthetic induction with etomidate. Anaesth Intensive Care 1988; 16:171.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/44\" class=\"nounderline abstract_t\">Schwarzkopf KR, Hueter L, Simon M, Fritz HG. Midazolam pretreatment reduces etomidate-induced myoclonic movements. Anaesth Intensive Care 2003; 31:18.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/45\" class=\"nounderline abstract_t\">Cohan P, Wang C, McArthur DL, et al. Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med 2005; 33:2358.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/46\" class=\"nounderline abstract_t\">den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90:5110.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/47\" class=\"nounderline abstract_t\">Jackson WL Jr. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal. Chest 2005; 127:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/48\" class=\"nounderline abstract_t\">Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/49\" class=\"nounderline abstract_t\">Basciani RM, Rindlisbacher A, Begert E, et al. Anaesthetic induction with etomidate in cardiac surgery: A randomised controlled trial. Eur J Anaesthesiol 2016; 33:417.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/50\" class=\"nounderline abstract_t\">Bruder EA, Ball IM, Ridi S, et al. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev 2015; 1:CD010225.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/51\" class=\"nounderline abstract_t\">Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/52\" class=\"nounderline abstract_t\">Fragen RJ, Weiss HW, Molteni A. The effect of propofol on adrenocortical steroidogenesis: a comparative study with etomidate and thiopental. Anesthesiology 1987; 66:839.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/53\" class=\"nounderline abstract_t\">Jameson P, Desborough JP, Bryant AE, Hall GM. The effect of cortisol suppression on interleukin-6 and white blood cell responses to surgery. Acta Anaesthesiol Scand 1997; 41:304.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/54\" class=\"nounderline abstract_t\">Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/55\" class=\"nounderline abstract_t\">Komatsu R, You J, Mascha EJ, et al. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg 2013; 117:1329.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/56\" class=\"nounderline abstract_t\">Heinrich S, Schmidt J, Ackermann A, et al. Comparison of clinical outcome variables in patients with and without etomidate-facilitated anesthesia induction ahead of major cardiac surgery: a retrospective analysis. Crit Care 2014; 18:R150.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/57\" class=\"nounderline abstract_t\">Wagner CE, Bick JS, Johnson D, et al. Etomidate use and postoperative outcomes among cardiac surgery patients. Anesthesiology 2014; 120:579.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/58\" class=\"nounderline abstract_t\">Gu WJ, Wang F, Tang L, Liu JC. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest 2015; 147:335.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/59\" class=\"nounderline abstract_t\">Komatsu R, You J, Rajan S, et al. Steroid administration after anaesthetic induction with etomidate does not reduce in-hospital mortality or cardiovascular morbidity after non-cardiac surgery. Br J Anaesth 2018; 120:501.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/60\" class=\"nounderline abstract_t\">Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/61\" class=\"nounderline abstract_t\">Kaneda K, Yamashita S, Woo S, Han TH. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. J Clin Pharmacol 2011; 51:482.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/62\" class=\"nounderline abstract_t\">Van Hamme MJ, Ghoneim MM, Ambre JJ. Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology 1978; 49:274.</a></li><li class=\"breakAll\">Perouansky M, Hemmings HC. Intravenous anaesthetic agents. In: Foundations of Anesthesia, 2nd ed, Hemmings HC, Hopkins PM (Eds), Elsevier, Philadelphia 2006. p.295.</li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/64\" class=\"nounderline abstract_t\">Gray LD, Morris C. The principles and conduct of anaesthesia for emergency surgery. Anaesthesia 2013; 68 Suppl 1:14.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/65\" class=\"nounderline abstract_t\">Morris C, Perris A, Klein J, Mahoney P. Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent? Anaesthesia 2009; 64:532.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/66\" class=\"nounderline abstract_t\">Pandit JJ. Intravenous anaesthetic agents. Anaesthesia and Intensive Care Medicine 2007; 9:154.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/67\" class=\"nounderline abstract_t\">Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/68\" class=\"nounderline abstract_t\">Rogers R, Wise RG, Painter DJ, et al. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004; 100:292.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/69\" class=\"nounderline abstract_t\">L&aring;ngsj&ouml; JW, Kaisti KK, Aalto S, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99:614.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/70\" class=\"nounderline abstract_t\">Hanouz JL, Persehaye E, Zhu L, et al. The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth Analg 2004; 99:1689.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/71\" class=\"nounderline abstract_t\">Hanouz JL, Zhu L, Persehaye E, et al. Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors. Anesthesiology 2005; 102:1190.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/72\" class=\"nounderline abstract_t\">Chen RM, Chen TL, Lin YL, et al. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Care Med 2005; 33:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/73\" class=\"nounderline abstract_t\">Weiskopf RB, Bogetz MS, Roizen MF, Reid IA. Cardiovascular and metabolic sequelae of inducing anesthesia with ketamine or thiopental in hypovolemic swine. Anesthesiology 1984; 60:214.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/74\" class=\"nounderline abstract_t\">Corssen G, Gutierrez J, Reves JG, Huber FC Jr. Ketamine in the anesthetic management of asthmatic patients. Anesth Analg 1972; 51:588.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/75\" class=\"nounderline abstract_t\">Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/76\" class=\"nounderline abstract_t\">Eikermann M, Grosse-Sundrup M, Zaremba S, et al. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. Anesthesiology 2012; 116:35.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/77\" class=\"nounderline abstract_t\">Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; :CD004603.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/78\" class=\"nounderline abstract_t\">Loftus RW, Yeager MP, Clark JA, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology 2010; 113:639.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/79\" class=\"nounderline abstract_t\">McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med 2011; 12:1551.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/80\" class=\"nounderline abstract_t\">Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103:147.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/81\" class=\"nounderline abstract_t\">Gooding JM, Dimick AR, Tavakoli M, Corssen G. A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients. Anesth Analg 1977; 56:813.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/82\" class=\"nounderline abstract_t\">Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998; 88:82.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/83\" class=\"nounderline abstract_t\">Kleinloog D, Uit den Boogaard A, Dahan A, et al. Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers. J Psychopharmacol 2015; 29:401.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/84\" class=\"nounderline abstract_t\">Grace RF. The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia. Anaesthesia 2003; 58:904.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/85\" class=\"nounderline abstract_t\">Gardner AE, Dannemiller FJ, Dean D. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia. Anesth Analg 1972; 51:741.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/86\" class=\"nounderline abstract_t\">L&aring;ngsj&ouml; JW, Salmi E, Kaisti KK, et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 2004; 100:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/87\" class=\"nounderline abstract_t\">Hudetz JA, Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. J Cardiothorac Vasc Anesth 2010; 24:131.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/88\" class=\"nounderline abstract_t\">Yan J, Jiang H. Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain. J Neurosurg Anesthesiol 2014; 26:155.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/89\" class=\"nounderline abstract_t\">Green SM, Cot&eacute; CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med 2009; 54:181.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/90\" class=\"nounderline abstract_t\">Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg 2005; 101:524.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/91\" class=\"nounderline abstract_t\">Cheng DC. The drug addicted patient. Can J Anaesth 1997; 44:R101.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/92\" class=\"nounderline abstract_t\">Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95:114.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/93\" class=\"nounderline abstract_t\">Herd DW, Anderson BJ, Keene NA, Holford NH. Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth 2008; 18:36.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/94\" class=\"nounderline abstract_t\">Cohen ML, Trevor AJ. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 1974; 189:351.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/95\" class=\"nounderline abstract_t\">White PF, Sch&uuml;ttler J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 1985; 57:197.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/96\" class=\"nounderline abstract_t\">Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 1981; 53:27.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/97\" class=\"nounderline abstract_t\">Grant IS, Nimmo WS, McNicol LR, Clements JA. Ketamine disposition in children and adults. Br J Anaesth 1983; 55:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/98\" class=\"nounderline abstract_t\">Taylor C, Stoelting VK. Methohexital sodium - a new ultrashort acting barbiturate. Anesthesiology 1960; 21:29.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/99\" class=\"nounderline abstract_t\">Harrison GG, Meissner PN, Hift RJ. Anaesthesia for the porphyric patient. Anaesthesia 1993; 48:417.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/100\" class=\"nounderline abstract_t\">Kelly HE, Shaw GM, Brett CN, et al. The effect of titrated fentanyl on suppressed cough reflex in healthy adult volunteers. Anaesthesia 2016; 71:529.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/101\" class=\"nounderline abstract_t\">Chung KS, Sinatra RS, Halevy JD, et al. A comparison of fentanyl, esmolol, and their combination for blunting the haemodynamic responses during rapid-sequence induction. Can J Anaesth 1992; 39:774.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/102\" class=\"nounderline abstract_t\">Cork RC, Weiss JL, Hameroff SR, Bentley J. Fentanyl preloading for rapid-sequence induction of anesthesia. Anesth Analg 1984; 63:60.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/103\" class=\"nounderline abstract_t\">Dahlgren N, Messeter K. Treatment of stress response to laryngoscopy and intubation with fentanyl. Anaesthesia 1981; 36:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/104\" class=\"nounderline abstract_t\">Kazama T, Ikeda K, Morita K. The pharmacodynamic interaction between propofol and fentanyl with respect to the suppression of somatic or hemodynamic responses to skin incision, peritoneum incision, and abdominal wall retraction. Anesthesiology 1998; 89:894.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/105\" class=\"nounderline abstract_t\">Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81:820.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/106\" class=\"nounderline abstract_t\">Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992; 69:162.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/107\" class=\"nounderline abstract_t\">Kazama T, Ikeda K, Morita K. Reduction by fentanyl of the Cp50 values of propofol and hemodynamic responses to various noxious stimuli. Anesthesiology 1997; 87:213.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/108\" class=\"nounderline abstract_t\">Van Aken H, Meinshausen E, Prien T, et al. The influence of fentanyl and tracheal intubation on the hemodynamic effects of anesthesia induction with propofol/N2O in humans. Anesthesiology 1988; 68:157.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/109\" class=\"nounderline abstract_t\">STEINHAUS JE, GASKIN L. A study of intravenous lidocaine as a suppressant of cough reflex. Anesthesiology 1963; 24:285.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/110\" class=\"nounderline abstract_t\">Aouad MT, Sayyid SS, Zalaket MI, Baraka AS. Intravenous lidocaine as adjuvant to sevoflurane anesthesia for endotracheal intubation in children. Anesth Analg 2003; 96:1325.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/111\" class=\"nounderline abstract_t\">Davidson JA, Gillespie JA. Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine. Br J Anaesth 1993; 70:163.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/112\" class=\"nounderline abstract_t\">Jakobsen CJ, Ahlburg P, Holdg&aring;rd HO, et al. Comparison of intravenous and topical lidocaine as a suppressant of coughing after bronchoscopy during general anesthesia. Acta Anaesthesiol Scand 1991; 35:238.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/113\" class=\"nounderline abstract_t\">Lin CS, Sun WZ, Chan WH, et al. Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough. Can J Anaesth 2004; 51:654.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/114\" class=\"nounderline abstract_t\">Nishino T, Hiraga K, Sugimori K. Effects of i.v. lignocaine on airway reflexes elicited by irritation of the tracheal mucosa in humans anaesthetized with enflurane. Br J Anaesth 1990; 64:682.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/115\" class=\"nounderline abstract_t\">Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine suppresses fentanyl-induced coughing: a double-blind, prospective, randomized placebo-controlled study. Anesth Analg 2004; 99:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/116\" class=\"nounderline abstract_t\">Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine 0.5 mg.kg-1 effectively suppresses fentanyl-induced cough. Can J Anaesth 2005; 52:172.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/117\" class=\"nounderline abstract_t\">Warner LO, Balch DR, Davidson PJ. Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane-nitrous oxide? J Clin Anesth 1997; 9:270.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/118\" class=\"nounderline abstract_t\">Yukioka H, Hayashi M, Terai T, Fujimori M. Intravenous lidocaine as a suppressant of coughing during tracheal intubation in elderly patients. Anesth Analg 1993; 77:309.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/119\" class=\"nounderline abstract_t\">Adamzik M, Groeben H, Farahani R, et al. Intravenous lidocaine after tracheal intubation mitigates bronchoconstriction in patients with asthma. Anesth Analg 2007; 104:168.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/120\" class=\"nounderline abstract_t\">Chang HY, Togias A, Brown RH. The effects of systemic lidocaine on airway tone and pulmonary function in asthmatic subjects. Anesth Analg 2007; 104:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/121\" class=\"nounderline abstract_t\">Maslow AD, Regan MM, Israel E, et al. Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. Anesthesiology 2000; 93:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/122\" class=\"nounderline abstract_t\">Senturk M, Pembeci K, Menda F, et al. Effects of intramuscular administration of lidocaine or bupivacaine on induction and maintenance doses of propofol evaluated by bispectral index. Br J Anaesth 2002; 89:849.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/123\" class=\"nounderline abstract_t\">Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118:69.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/124\" class=\"nounderline abstract_t\">Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology 1985; 62:310.</a></li><li><a href=\"https://www.uptodate.com/contents/general-anesthesia-intravenous-induction-agents/abstract/125\" class=\"nounderline abstract_t\">Forster A, Gardaz JP, Suter PM, Gemperle M. Respiratory depression by midazolam and diazepam. Anesthesiology 1980; 53:494.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 94533 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3792454773\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1503167298\" id=\"outline-link-H1503167298\">INTRODUCTION</a></li><li><a href=\"#H4070595924\" id=\"outline-link-H4070595924\">DOSING CONSIDERATIONS</a></li><li><a href=\"#H2269410\" id=\"outline-link-H2269410\">PROPOFOL</a><ul><li><a href=\"#H2657717339\" id=\"outline-link-H2657717339\">Advantages</a></li><li><a href=\"#H2269447\" id=\"outline-link-H2269447\">Adverse effects</a></li><li><a href=\"#H1745064393\" id=\"outline-link-H1745064393\">Drug-drug interactions</a></li><li><a href=\"#H165838481\" id=\"outline-link-H165838481\">Pharmacokinetics</a></li><li><a href=\"#H1872411706\" id=\"outline-link-H1872411706\">Dosing</a></li></ul></li><li><a href=\"#H307136729\" id=\"outline-link-H307136729\">ETOMIDATE</a><ul><li><a href=\"#H3248597381\" id=\"outline-link-H3248597381\">Advantages</a></li><li><a href=\"#H262499028\" id=\"outline-link-H262499028\">Adverse effects</a></li><li><a href=\"#H242460226\" id=\"outline-link-H242460226\">Drug-drug interactions</a></li><li><a href=\"#H3348275065\" id=\"outline-link-H3348275065\">Pharmacokinetics</a></li><li><a href=\"#H4201415421\" id=\"outline-link-H4201415421\">Dosing</a></li></ul></li><li><a href=\"#H2269465\" id=\"outline-link-H2269465\">KETAMINE</a><ul><li><a href=\"#H887839396\" id=\"outline-link-H887839396\">Advantages</a></li><li><a href=\"#H2269513\" id=\"outline-link-H2269513\">Adverse effects</a><ul><li><a href=\"#H3402618051\" id=\"outline-link-H3402618051\">- Cardiovascular effects</a></li><li><a href=\"#H3058808067\" id=\"outline-link-H3058808067\">- Neurologic effects</a></li><li><a href=\"#H4195246664\" id=\"outline-link-H4195246664\">- Other effects</a></li></ul></li><li><a href=\"#H1385138965\" id=\"outline-link-H1385138965\">Drug-drug interactions</a></li><li><a href=\"#H3610684087\" id=\"outline-link-H3610684087\">Pharmacokinetics</a></li><li><a href=\"#H1177223154\" id=\"outline-link-H1177223154\">Dosing</a></li></ul></li><li><a href=\"#H181245995\" id=\"outline-link-H181245995\">METHOHEXITAL</a><ul><li><a href=\"#H3311352297\" id=\"outline-link-H3311352297\">Advantages</a></li><li><a href=\"#H356478373\" id=\"outline-link-H356478373\">Adverse effects</a></li><li><a href=\"#H2613619630\" id=\"outline-link-H2613619630\">Drug-drug interactions</a></li><li><a href=\"#H2621093711\" id=\"outline-link-H2621093711\">Pharmacokinetics</a></li><li><a href=\"#H3270637583\" id=\"outline-link-H3270637583\">Dosing</a></li></ul></li><li><a href=\"#H2272654275\" id=\"outline-link-H2272654275\">ADJUVANT AGENTS</a><ul><li><a href=\"#H240924670\" id=\"outline-link-H240924670\">Opioids</a></li><li><a href=\"#H1973711502\" id=\"outline-link-H1973711502\">Lidocaine</a></li><li><a href=\"#H818607874\" id=\"outline-link-H818607874\">Midazolam</a></li></ul></li><li><a href=\"#H288547807\" id=\"outline-link-H288547807\">SELECTION OF INDUCTION AGENTS</a></li><li><a href=\"#H3792454773\" id=\"outline-link-H3792454773\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/94533|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/102350\" class=\"graphic graphic_table\">- Intravenous anesthetic induction agents</a></li><li><a href=\"image.htm?imageKey=ANEST/107796\" class=\"graphic graphic_table\">- Stages of anesthetic depth</a></li><li><a href=\"image.htm?imageKey=ANEST/106541\" class=\"graphic graphic_table\">- IV adjuvant agents for induction of general anesthesia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-adult-patients-with-asthma\" class=\"medical medical_review\">Anesthesia for adult patients with asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-adult-patients-with-hypertension\" class=\"medical medical_review\">Anesthesia for adult patients with hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-craniotomy\" class=\"medical medical_review\">Anesthesia for craniotomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-intracranial-neurovascular-procedures-in-adults\" class=\"medical medical_review\">Anesthesia for intracranial neurovascular procedures in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease\" class=\"medical medical_review\">Anesthesia for noncardiac surgery in patients with ischemic heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-patients-with-acute-traumatic-brain-injury\" class=\"medical medical_review\">Anesthesia for patients with acute traumatic brain injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-adult-with-pheochromocytoma\" class=\"medical medical_review\">Anesthesia for the adult with pheochromocytoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-older-adult\" class=\"medical medical_review\">Anesthesia for the older adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis\" class=\"medical medical_review\">Anesthesia for the patient on dialysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-patient-with-liver-disease\" class=\"medical medical_review\">Anesthesia for the patient with liver disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-induction\" class=\"medical medical_review\">General anesthesia: Induction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence\" class=\"medical medical_review\">General anesthesia: Maintenance and emergence</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucocorticoid-therapy-in-septic-shock\" class=\"medical medical_review\">Glucocorticoid therapy in septic shock</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">Induction agents for rapid sequence intubation in adults outside the operating room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-management-of-shock-in-adults\" class=\"medical medical_review\">Intraoperative management of shock in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-perioperative-pain\" class=\"medical medical_review\">Management of acute perioperative pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuromonitoring-in-surgery-and-anesthesia\" class=\"medical medical_review\">Neuromonitoring in surgery and anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management\" class=\"medical medical_review\">Perioperative anaphylaxis: Clinical manifestations, etiology, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-uses-of-intravenous-opioids-in-adults\" class=\"medical medical_review\">Perioperative uses of intravenous opioids in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postoperative-nausea-and-vomiting\" class=\"medical medical_review\">Postoperative nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=procedural-sedation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">Procedural sedation in adults outside the operating room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia\" class=\"medical medical_review\">Rapid sequence induction and intubation (RSII) for anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults\" class=\"medical medical_review\">Technique for performing electroconvulsive therapy (ECT) in adults</a></li></ul></div></div>","javascript":null}